Evidence for the epoxide-diol pathway in the biotransformation of mephenytoin. 1979

N Gerber, and R M Thompson, and R G Smith, and R K Lynn

A dihydrodiol metabolite of mephenytoin (5-dihydroxycyclohexadienyl)-5-ethyl-3-methylhydantoin and other mono- and dihydroxylated and N-demethylated metabolites were identified in urine from a male epileptic patient receiving therapy with mephenytoin (300 mg/day). Metabolites, extracted from urine before and after enzymatic hydrolysis, were derivatized with a trimethylsilyl reagent and analyzed by combined gas chromatography and mass spectrometry. Two previously unreported metabolites were characterized: 5-ethyl-5-(di-hydroxyphenyl)-3-methylhydantoin and 5-ethyl-5-(hydroxy-methoxy-phenyl)-3-methylhydantoin. The structures of several other metabolites were confirmed: N-demethylmephenytoin, 5-ethyl-5-hydroxyphenylhydantoin, 5-ethyl-5-hydroxyphenyl-3-methylhydantoin and mephenytoin dihyrodiol. The dihydrodiol metabolite was of special interest since it was probably produced via an epoxide intermediate, 5-(epoxy-cyclohexadienyl)-5-ethyl-3-methylhydantoin. Previous reports have demonstrated that epoxides of this structural class are extremely reactive compounds, capable of alkylating biologic macromolecules. Covalent binding of the mephenytoin epoxide to macromolecules may be an important factor in the production of adverse and sometimes fatal side effects observed in patients receiving long-term therapy with mephenytoin.

UI MeSH Term Description Entries
D008297 Male Males
D008617 Mephenytoin An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Methoin,Methyl Phenetoin,5-Ethyl-3-Methyl-5-Phenylhydantoin,Mefenetoin,Mesantoin,Phenantoin,5 Ethyl 3 Methyl 5 Phenylhydantoin,Phenetoin, Methyl
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006827 Hydantoins Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS. Hydantoin,Imidazolidine-2,4-Diones,Imidazolidine 2,4 Diones
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

N Gerber, and R M Thompson, and R G Smith, and R K Lynn
October 1980, Xenobiotica; the fate of foreign compounds in biological systems,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
February 1984, Epilepsia,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
August 1976, The Journal of pharmacy and pharmacology,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
April 1977, Journal of chromatography,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
November 1980, Xenobiotica; the fate of foreign compounds in biological systems,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
May 1979, Xenobiotica; the fate of foreign compounds in biological systems,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
March 1980, Xenobiotica; the fate of foreign compounds in biological systems,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
January 1975, Drug metabolism and disposition: the biological fate of chemicals,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
March 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
N Gerber, and R M Thompson, and R G Smith, and R K Lynn
April 1977, Journal of chromatography,
Copied contents to your clipboard!